HDAC9 and pancreatic neoplasm: As an HDAC inhibitor that exhibits potent inhibitory activities against HDAC enzymes, CG-745 has been investigated for a novel molecular targeted anti-cancer therapeutic candidate in pancreatic cancer and myelodysplastic syndrome.